Inventiva S.A. (LON:0RNK)
London
· Delayed Price · Currency is GBP · Price in EUR 3.170
-0.060 (-1.86%)
Apr 24, 2025, 1:25 PM BST
Inventiva Revenue
In the year 2024, Inventiva had annual revenue of 14.09M EUR, down -38.24%. Inventiva had revenue of 11.36M in the half year ending December 31, 2024, a decrease of -26.34%.
Revenue
14.09M EUR
Revenue Growth
-38.24%
P/S Ratio
22.14
Revenue / Employee
119.44K EUR
Employees
118
Market Cap
258.05M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.09M | -8.73M | -38.24% |
| Dec 31, 2023 | 22.82M | 4.77M | 26.41% |
| Dec 31, 2022 | 18.05M | 9.55M | 112.35% |
| Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
| Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.19B |
| GSK plc | 31.38B |
| Haleon | 11.23B |
| Smith & Nephew | 4.64B |
| ConvaTec Group | 1.83B |
| Hikma Pharmaceuticals | 2.50B |
| HUTCHMED (China) | 503.39M |
| Oxford Nanopore Technologies | 183.19M |
Inventiva News
- 23 days ago - Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis - GlobeNewsWire
- 4 weeks ago - Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Inventiva reports its 2024 full year results and provides a business update - GlobeNewsWire
- 5 weeks ago - Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results - GlobeNewsWire
- 2 months ago - Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment - GlobeNewsWire
- 2 months ago - Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial - GlobeNewsWire
- 2 months ago - Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update - GlobeNewsWire
- 3 months ago - Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology - GlobeNewsWire